Clinical Trial Update: The ALA, DHA and EPA Esters in the Prevention of Cardiovascular Diseases. [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the ALA, DHA, and EPA esters for prevention of cardiovascular diseases is in progress; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases

Drugs mentioned

• ALA esters (alpha-linolenic acid esters) (alpha-linolenic acid esters)
• DHA esters (docosahexaenoic acid esters) (docosahexaenoic acid esters)
• EPA esters (eicosapentaenoic acid esters) (eicosapentaenoic acid esters)

Snippet

Sponsor: Wroclaw Medical University | Conditions: Fatty Acids, Alpha-Linolenic Acid | Phase 3 | Status: UNKNOWN